GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AFT Pharmaceuticals Ltd (ASX:AFP) » Definitions » Return-on-Tangible-Asset

AFT Pharmaceuticals (ASX:AFP) Return-on-Tangible-Asset : 3.42% (As of Sep. 2023)


View and export this data going back to 2015. Start your Free Trial

What is AFT Pharmaceuticals Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. AFT Pharmaceuticals's annualized Net Income for the quarter that ended in Sep. 2023 was A$3.4 Mil. AFT Pharmaceuticals's average total tangible assets for the quarter that ended in Sep. 2023 was A$98.0 Mil. Therefore, AFT Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2023 was 3.42%.

The historical rank and industry rank for AFT Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:

ASX:AFP' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -30.94   Med: 3.46   Max: 25.43
Current: 11.18

During the past 8 years, AFT Pharmaceuticals's highest Return-on-Tangible-Asset was 25.43%. The lowest was -30.94%. And the median was 3.46%.

ASX:AFP's Return-on-Tangible-Asset is ranked better than
84.12% of 1083 companies
in the Drug Manufacturers industry
Industry Median: 1.88 vs ASX:AFP: 11.18

AFT Pharmaceuticals Return-on-Tangible-Asset Historical Data

The historical data trend for AFT Pharmaceuticals's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AFT Pharmaceuticals Return-on-Tangible-Asset Chart

AFT Pharmaceuticals Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Return-on-Tangible-Asset
Get a 7-Day Free Trial -4.61 22.09 11.48 25.50 11.44

AFT Pharmaceuticals Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.13 39.84 3.38 20.16 3.42

Competitive Comparison of AFT Pharmaceuticals's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AFT Pharmaceuticals's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where AFT Pharmaceuticals's Return-on-Tangible-Asset falls into.



AFT Pharmaceuticals Return-on-Tangible-Asset Calculation

AFT Pharmaceuticals's annualized Return-on-Tangible-Asset for the fiscal year that ended in Mar. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Mar. 2023 )  (A: Mar. 2022 )(A: Mar. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Mar. 2023 )  (A: Mar. 2022 )(A: Mar. 2023 )
=9.907/( (77.92+95.25)/ 2 )
=9.907/86.585
=11.44 %

AFT Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Sep. 2023 )  (Q: Mar. 2023 )(Q: Sep. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Sep. 2023 )  (Q: Mar. 2023 )(Q: Sep. 2023 )
=3.352/( (95.25+100.738)/ 2 )
=3.352/97.994
=3.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Sep. 2023) net income data.


AFT Pharmaceuticals  (ASX:AFP) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


AFT Pharmaceuticals Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of AFT Pharmaceuticals's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


AFT Pharmaceuticals (ASX:AFP) Business Description

Traded in Other Exchanges
Address
129 Hurstmere Road, Level 1, Takapuna, Auckland, NTL, NZL, 0622
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Aqueous cream, Calci-tab, Maxigesic, Cromo-fresh, Crystaderm, Crytawash, Ellgy plus, Emulsifying ointment, and others. The group has four operating segments based on geographical location being, Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia which includes the sales and distribution activity relating to the Australian market.

AFT Pharmaceuticals (ASX:AFP) Headlines

No Headlines